Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.
The relative efficacy of quintuple and sextuple buprenorphine dosing in abating withdrawal symptoms for 120 h was compared in opioid-dependent outpatients. Fourteen subjects received buprenorphine in a double-blind, placebo-controlled, cross-over design. Daily sublingual maintenance doses were 4 mg/70 kg (n=4) and 8 mg/70 kg (n=10). After a stabilization period of daily maintenance administration, subjects received quintuple (5x daily maintenance dose) and sextuple (6x daily maintenance dose) doses every 120 h. Measures of opioid agonist and withdrawal effects were assessed daily. Subjective ratings of withdrawal were significantly greater than baseline ratings beyond 96-h post dosing under both regimens. There was no evidence, however, that those subjective ratings of withdrawal differed between the two regimens. Thus, these data suggest that sextuple buprenorphine dosing, administered every 5 days, does not abate opioid-withdrawal beyond 96 hours.
Gross
A
A
Substance Abuse Treatment Center, University of Vermont, 1 South Prospect Street, Burlington, VT 05401, USA. agross@zoo.uvm.edu
Jacobs
E A
EA
Petry
N M
NM
Badger
G J
GJ
Bickel
W K
WK
D000328:Adult; D000704:Analysis of Variance; D002047:Buprenorphine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
D002047:Buprenorphine